Reviewer’s report

Title: Clinical significance of HER2 and EGFR expression in Colorectal Cancer Patients with Ovarian Metastasis

Version: 0 Date: 19 Dec 2018

Reviewer: Atif Ahmed

Reviewer's report:

Minor revisions are needed, summarized below:

1. The authors have evaluated HER2 and EGFR expression in the metastatic tumors and compared them to the primary tumors. It seems that there are some cases that gained or lost HER2 expression and others gained or lost EGFR expression in the metastatic tumors. The authors provided detailed analysis on paired primary and metastatic specimens for HER2 in the discussion section. These should be moved to the results section and analysis of paired specimens for EGFR expression should also be evaluated in the results section.

2. Table 2 mentions lymph nodes. Please specify the location of the lymph nodes (e.g. mesenteric, pelvic, etc). Please specify the meaning of the lymph nodes grouping into 0, 1-5 or >5. Are the authors talking about the number of positive mesenteric lymph nodes?

3. Fig 1 is blurry and the IHC figures are not clear. The reader cannot tell cytoplasmic versus membranous staining.

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Yes

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Yes
Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I am able to assess the statistics

**Quality of written English**
Please indicate the quality of language in the manuscript:

Needs some language corrections before being published

**Declaration of competing interests**
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?
If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal